Cellectar Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cellectar Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.79M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($44.58M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($42.77M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($17.52M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($10.18M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($7.19M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($31.79M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($7.51M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($5.64M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($6.24M) | Oct 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.98M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($51.78M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($38.96M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($9.41M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($8.29M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($8.71M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($28.81M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($7.82M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($7.44M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($6.14M) | Oct 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.50M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $26.14M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $27.27M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $7.03M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $6.14M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $6.36M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $18.27M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $5.21M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $4.14M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $3.70M | Oct 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.12M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($47.58M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($32.38M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($22.78M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($14.71M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($7.18M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($25.22M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($17.81M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($10.80M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($5.04M) | Oct 29, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.9K | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $104.2K | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $864.0K | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $597.3K | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $226.0K | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $108.1K | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $101.0K | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $30.1K | Oct 29, 2024 |
| FY2022 | Dec 31, 2021 | $141.4K | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $62.4K | Mar 21, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.98M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $25.47M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $12.08M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $21.55M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $6.51M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $14.84M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $21.59M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $19.32M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $25.89M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $31.99M | Oct 29, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.06M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $9.80M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $25.85M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $30.35M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $13.52M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $12.09M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $12.05M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $7.17M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $6.60M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $7.48M | Oct 29, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.54M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $14.29M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | ($15.16M) | Mar 4, 2026 |
| FY2023 | Sep 30, 2023 | ($28.00M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($8.39M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $1.37M | Oct 29, 2024 |
| FY2024 | Dec 31, 2022 | $8.15M | Mar 13, 2025 |
| FY2023 | Sep 30, 2022 | $10.77M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $17.91M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $23.13M | Oct 29, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 9, 2020 |
| FY2019 | Dec 31, 2018 | $0 | Mar 9, 2020 |
| FY2018 | Dec 31, 2017 | $1.68M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.68M | Mar 21, 2018 |
| FY2016 | Dec 31, 2015 | $1.68M | Mar 15, 2017 |
| FY2015 | Dec 31, 2014 | $1.68M | Oct 20, 2016 |
| FY2014 | Dec 31, 2013 | $1.68M | May 20, 2015 |
| FY2013 | Dec 31, 2012 | $1.68M | Mar 19, 2014 |
| FY2012 | Dec 31, 2011 | $1.68M | Mar 28, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($269.13M) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | ($247.34M) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($202.76M) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | ($194.88M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | ($177.36M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | ($167.18M) | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | ($159.99M) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | ($147.58M) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | ($140.07M) | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | ($134.44M) | Oct 29, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $23.29M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $9.56M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | $18.99M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | $5.15M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | $12.68M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | $19.87M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | $17.79M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | $24.81M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | $30.63M | Oct 29, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $330.2K | Oct 20, 2016 |
| FY2014 | Dec 31, 2014 | $450.0K | May 20, 2015 |
| FY2013 | Dec 31, 2013 | $450.0K | Mar 19, 2014 |
| FY2012 | Dec 31, 2012 | $450.0K | Mar 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (36) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Oct 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (8) | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | (41) | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | (4) | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Oct 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.24M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 1.54M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | 20.74M | Mar 13, 2025 |
| FY2023 | Sep 30, 2023 | 9.92M | Oct 29, 2024 |
| FY2023 | Jun 30, 2023 | 9.74M | Oct 29, 2024 |
| FY2023 | Mar 31, 2023 | 9.74M | Oct 29, 2024 |
| FY2023 | Dec 31, 2022 | 9.39M | Oct 29, 2024 |
| FY2023 | Sep 30, 2022 | 6.11M | Oct 29, 2024 |
| FY2023 | Jun 30, 2022 | 6.11M | Oct 29, 2024 |
| FY2023 | Mar 31, 2022 | 6.11M | Oct 29, 2024 |